Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;10(1):63-71.
doi: 10.1007/s13555-020-00354-2. Epub 2020 Jan 18.

Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice

Affiliations
Review

Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice

Thrasyvoulos Tzellos et al. Dermatol Ther (Heidelb). 2020 Feb.

Erratum in

Abstract

Hidradenitis suppurativa (HS) is a chronic, recurrent skin inflammatory disease associated with a variety of comorbidities, like reduced quality of life, metabolic syndrome, sexual dysfunction, working disability, axial spondyloarthritis, inflammatory bowel disease, depression, and anxiety. Like psoriasis, HS patients have been found to have higher risk of cardiovascular death and suicide risk. Clinicians should be informed about these comorbidities so that appropriate screening is implemented. All this evidence suggests that for such a chronic, multi-comorbid disease, the use of validated outcomes to assess severity and effect of treatment, along with the use of clinically important patient reported outcomes, is essential. The potential of available treatments to negatively and positively affect these comorbidities should also be taken into account when designing treatment strategies. This review provides an outline of important HS comorbidities with emphasis on possible implications for daily clinical practice.

Keywords: Clinical significance; Comorbidities; Depression; Hidradenitis suppurativa; Inflammatory bowel disease; Metabolic syndrome; Quality of life; Working disability.

PubMed Disclaimer

Conflict of interest statement

Thrasyvoulos Tzellos has acted as advisory board member for AbbVie and UCB. Christos Zouboulis received honoraria from AbbVie, Bayer Healthcare, Biogen and PPM for participation as an advisor and speaker; from Allergan, Almirall, Celgene, GSK, Inflarx, Novartis and UCB for participation as an advisor; and from Jenapharm and Pierre Fabre for participation as a speaker.

References

    1. Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–164. doi: 10.1056/NEJMcp1014163. - DOI - PubMed
    1. Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184–190. doi: 10.1159/000431175. - DOI - PubMed
    1. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa) Dermatoendocrinol. 2010;2:9–16. doi: 10.4161/derm.2.1.12490. - DOI - PMC - PubMed
    1. Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73:S4–S7. doi: 10.1016/j.jaad.2015.07.052. - DOI - PubMed
    1. Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546–1549. doi: 10.1111/bjd.14038. - DOI - PubMed

LinkOut - more resources